安斯泰来（Astellas）1月15日宣布，在日本推出Irribow OD片2.5ug/5ug（通用名：盐酸雷莫司琼，ramosetron hydrochloride），该药为口服崩解片（orally disintegrating，OD）剂型，于2013年8月获日本批准，作为一种新配方Irribow片，用于腹泻型肠易激综合征2（IBS-D）男性患者的治疗。

Irribow OD片利用安斯泰来专有的药物递送技术WOWTAB开发，该药在接触口腔唾液时刻迅速崩解，因此无需喝水即可咀嚼。对于老年患者及有吞咽困难的患者来说，该药也可以很容易地服药，同时还可以用于任何避免喝水的情况，满足患者的各种需求。

Irribow片是5羟色胺3（5-HT3）受体拮抗剂，由安斯泰来发现。5羟色胺是一种神经递质，与肠胃蠕动、分泌和感觉有很大关系。应激可能刺激血清素的释放，并激活肠道神经上的5-HT3受体，诱发肠道的加速运转，导致腹泻。此外，肠道内的压力也可诱导血清素释放，血清素会结合神经元终端的5-HT3受体，引发肠道痛觉并传递到中枢神经系统。

Irribow能够选择性地抑制5-HT3受体，从而改善与肠道加速转运相关的异常排便，该药还能通过抑制肠道痛觉的传输，改善内脏高敏感性。

英文原文

Tokyo, January 15, 2014 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that the orally disintegrating tablet “Irribow® OD 1) Tablets 2.5µg / 5µg” (generic name: ramosetron hydrochloride) become available in Japanese market today. They were approved for an additional formulation of Irribow® Tablet with the indication of diarrhea-predominant irritable bowel syndrome 2) (“IBS-D”) in male.

Irribow® OD Tablet is a drug for treating IBS-D developed using WOWTAB 3) which is one of the Astellas' proprietary drug delivery technologies. It can be ingested without water since it quickly disintegrates upon contact with saliva in the mouth. It can be easily taken even by elderly patients and patients with impaired swallowing function. It is also useful for patients with avoided water consumption and meets various needs of patients. Astellas offers Gaster® D Tablet for the treatment for peptic ulcers and gastritis, Harnal® D Tablet for the treatment for functional symptoms of benign prostatic hyperplasia and Vesicare® OD Tablet for overactive bladder, which were developed with using WOWTAB technology.

Irribow® Tablet is a serotonin 5-HT3 receptor antagonist discovered by Astellas. Serotonin is a member of neurotransmitter which is greatly related to gastrointestinal motility, secretion and sensation. Stress may stimulate the serotonin release and activate the 5-HT3 receptors on enteric nerve, which induces the acceleration of intestinal transit resulting in diarrhea. In addition, the increase in intracolonic pressure also induces serotonin release, and it will bind to 5-HT3 receptor at the terminal of afferent neuron, causing intestinal nociceptive transmission to central nervous system.

Irribow® Tablet improves abnormal defecation associated with the acceleration of intestinal transit by inhibiting 5-HT3 receptor selectively. It also improves visceral hypersensitivity by suppressing the transmission of intestinal nociception.

Astellas expects to further contribute to irritable bowel syndrome treatment by introducing Irribow® OD Tablet which can further improve the compliance with its more convenient dosing option.

Upon the launch of Irribow® OD Tablet, Astellas doesn’t revise its current fiscal year (from April 1, 2013 to March 31, 2014) financial forecasts.

1) OD = Orally Disintegrating

2) Irritable bowel syndrome (IBS) is a functional but not organic disorder which causes abdominal pain and/or discomfort with abnormal defecation including diarrhea and constipation. These gastrointestinal symptoms persist for a long period with frequent remissions and exacerbations. Abdominal pain/discomfort and abnormal defecation are often associated with many factors such as stress, which is considered to cause the acceleration of intestinal transit resulted from the over-activation of enteric nervous system.

3) WOWTAB = Without Water Tablet

Product outlines are as follows:

Brand name: Irribow® OD Tablets 2.5µg / Irribow® OD Tablets 5µg

Generic name: Ramosetron Hydrochloride

Indication: Diarrhea-predominant irritable bowel syndrome in males

Dosage regimen: The recommended oral dose for adult males is 5μg of ramosetron hydrochloride, once daily. The dosage can be increased or decreased depending on the patient’s symptoms with a maximum dosage of 10 µg a day.

Package:

Irribow® OD Tablets 2.5µg: 100 Tablets (10 tablets x 10 sheets)

Irribow® OD Tablets 5µg: 100 Tablets (10 tablets x 10 sheets)

Drug Price:

Irribow® OD Tablets 2.5µg: 85.80 Yen

Irribow® OD Tablets 5µg: 140.20 Yen

Date of NHI Price Listing: December 13, 2013

Date of Launch: January 15, 2014

With the objective of prevention of medical accidents, Astellas has adopted the user-friendly artwork on blisters, which make it easy to identify even when PTP sheet is pided, and worked on the improvements of medicine identification with (i) print of product name and dosage on each pocket (each medicine), (ii) ingenuity of letter size and color, (iii) display of efficacy and so on.  The color and design of Irribow® OD Tablet are easy to identify for persons with impaired color vision.

免责声明： 

      本文仅供专业人士学术交流探讨，不作为诊疗及用药依据。 

      如有侵权，请联系我们删除